Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $5.39 Analyst target: $11.40 Upside: 111.50%
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address unmet medical needs. The company is headquartered in Petah Tikva, Israel.
See the full interactive analysis & chart →Informational only — not investment advice.